Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06423794 · ClinicalTrials.gov registry record · Phase 2
BHV-7000 Open-Label Extension Bipolar Mania Study
A Phase 2 study, sponsored by Biohaven Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT06423794 is a Phase 2 study that was terminated before completion, run by Biohaven Therapeutics. The registered enrollment target is 94 participants.
The verdict
NCT06423794, a Phase 2 study, was terminated before completion, sponsored by Biohaven Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.
Interventions
- DRUG BHV-7000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2025-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06423794
The ClinicalTrials.gov registry entry for NCT06423794 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BHV-7000 is the first listed.
NCT06423794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06423794 about?
NCT06423794 is a clinical study titled "BHV-7000 Open-Label Extension Bipolar Mania Study". The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.
What is the current status of trial NCT06423794?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2024-06-24. Estimated completion is 2025-04-25.
What interventions are being tested in trial NCT06423794?
The interventions under investigation include: BHV-7000 (DRUG).
Who is sponsoring clinical trial NCT06423794?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.